Sagimet Biosciences (SGMT) Other Non-Current Assets (2022 - 2025)
Sagimet Biosciences' (SGMT) quarterly Other Non-Current Assets came in at $62000.0 in Q1 2025, up 129.63% quarter-over-quarter from $27000.0 in Q4 2022.
Sagimet Biosciences (SGMT) Other Non-Current Assets (2022 - 2025) Analysis & Trends
Sagimet Biosciences' Other Non-Current Assets history runs 2 years deep, the most recent figure standing at $62000.0 for Q1 2025.
- On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to $62000.0 in Q1 2025; TTM through Mar 2025 was $62000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $27000.0, changed N/A from the prior year.
- Other Non-Current Assets rose to $62000.0 in Q1 2025 per SGMT's latest filing, from $27000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $62000.0 in Q1 2025 and bottomed at $27000.0 in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Sagimet Biosciences | 228.24 Mn | 228.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 62,000.00 |
| Dec 31, 2022 | 27,000.00 |